Arthur Kuan, CG Oncology CEO

CG On­col­o­gy spot­lights on­colyt­ic virus com­bo da­ta ahead of full read­out due next year

CG On­col­o­gy has been qui­et­ly chug­ging along — on­ly giv­ing up­dates at se­quen­tial can­cer con­fer­ences ahead of a full read­out on its on­colyt­ic virus can­cer ther­a­py next year.

In its lat­est at SITC, the Irvine, CA-based biotech showed up with longer-term da­ta on its ther­a­py, CG0070, in com­bi­na­tion with Mer­ck’s Keytru­da. While the da­ta are still ear­ly, they sug­gest more dura­bil­i­ty where the biotech had ini­tial­ly turned heads on ef­fi­ca­cy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.